Key result
Sildenafil and high-dose continuous anakinra successfully treated a 7-year-old male with MIS-C complicated by pulmonary vasculitis, leading to rapid resolution of respiratory failure and extubation at 36 hours.
Why the study?
MIS-C is a newly identified entity with limited data on epidemiology, pathogenesis, and outcomes, and pulmonary involvement with acute respiratory failure is an unusual life-threatening complication.
Does sildenafil and high-dose anakinra improve respiratory failure and pulmonary hypertension in a pediatric patient with MIS-C and pulmonary vasculitis?
Case Report (n=1)
Does sildenafil and high-dose anakinra improve respiratory failure and pulmonary hypertension in a pediatric patient with MIS-C and pulmonary vasculitis?
Sildenafil and high-dose continuous anakinra may serve as an effective rescue therapy for MIS-C complicated by pulmonary vasculitis and severe respiratory failure.
Answers are grounded in this paper and cite their sources.
May serve as rescue option in refractory MIS-C vasculitis; leaves open confirmation in prospective trials.
Multisystem inflammatory syndrome in children (MIS-C) is a newly identified clinical entity still not very well known in terms of epidemiology, pathogenesis, and long-term outcome. Pulmonary involvement with acute respiratory failure is an unusual life-threatening complication of MIS-C, often a reason for admission to the pediatric intensive care unit (PICU) and the use of mechanical ventilation. We present a case of a 7-year-old male patient, previously healthy, hospitalized for MIS-C, treated with intravenous immunoglobulins (IVIG), high dose methylprednisolone, and anakinra. After 2 days of the aforementioned therapy, the patient presented with hypoxia (SatO2: 85% in ambient air room) and breathing difficulties. A chest computed tomography (CT) scan showed the presence of multiple bilateral basal parenchymal thickening and small basal pleural effusion and an arterial blood gas analysis revealed severe hypoxia (PaO2/FiO2 ratio, 170 mmHg). Because of a worsening of respiratory distress, the patient was transferred to the PICU, where invasive mechanical ventilation and a continuous infusion of anakinra (12 mg/kg/day) were started. An echocardiogram was performed, which showed an increase in pulmonary pressure (40 mmHg) with normal heart ejection fraction (55%), and the hypothesis of pulmonary vasculitis involving the pulmonary arterioles was made. Therefore, therapy with sildenafil (0.15 mg/kg/day) was promptly set up, with an immediate improvement of the clinical picture of respiratory failure, reduction of pulmonary pressure (23 mmHg), and subsequent extubation at 36 h with a regular clinical course until discharge. As far as we know, our case represents the first report of pulmonary vasculitis in an MIS-C patient. The use of sildenafil and high-dose continuous anakinra may represent a rescue therapy in cases of MIS-C with pulmonary vasculitis or with difficulty in extubation, allowing a short-term hospitalization in intensive care and improving the long-term outcome in these patients.
No takes yet. Share an insight, caveat, or question.
Torre et al. (2022) conducted a case report in Multisystem inflammatory syndrome in children (MIS-C) with pulmonary vasculitis (n=1). Sildenafil and high-dose anakinra was evaluated on Clinical improvement and reduction of pulmonary pressure. Sildenafil and high-dose continuous anakinra successfully treated a 7-year-old male with MIS-C complicated by pulmonary vasculitis, leading to rapid resolution of respiratory failure and extubation at 36 hours.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: